Copied
 
 
Formål
Formål
Selskabets formål er indkøb, distribution og styring af komparatormedicin og farmaceutiske forsyninger til kliniske forsøg, herunder bioteknologiske studier, og anden hertil forbundet aktivitet.
Sidst opdateret den 01.10.2018 og angivet som gældende fra 28.09.2018 (2038 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 01.10.2018 og angivet som gældende fra 28.09.2018 (2038 dage).
Ingen historik.
Branche
Branche
Engroshandel med medicinalvarer og sygeplejeartikler (464610).
Sidst opdateret den 01.10.2018 og angivet som gældende fra 28.09.2018 (2038 dage).
Ingen historik.
Revision
Revisionfravalgt
false.
Sidst opdateret den 06.01.2022 og angivet som gældende fra 05.01.2022 (843 dage).
HistorikStartStop
false05.01.2022
true28.09.201804.01.2022
Revisor
Revisor
BAKER TILLY DENMARK GODKENDT REVISIONSPARTNERSELSKAB
Sidst opdateret den 06.01.2022 og angivet som gældende fra 05.01.2022 (843 dage).
Ingen historik.
Form
Virksomhedsform
80.
Sidst opdateret den 01.10.2018 og angivet som gældende fra 28.09.2018 (2038 dage).
Ingen historik.
Kontakt
Ingen nuværende registrering.
Ingen historik.
Telefon
Ingen nuværende registrering.
Ingen historik.
Navne
Binavne
Binavne
Myoderm ApS.
Sidst opdateret den 21.09.2020 og angivet som gældende fra 21.09.2020 (1314 dage).
Ingen historik.
Tegningsregel
Tegningsregel
Selskabet tegnes af en direktør.
Sidst opdateret den 01.10.2018 og angivet som gældende fra 28.09.2018 (2038 dage).
Fortolkning (1 tegningsmulighed)
1 direktør
Ingen historik.
Ansatte
27.04.2024
Ingen historik.
Kapital
27.04.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Baker Tilly Denmark
Revisionsvirksomhedens CVR-nr.:35257691
Beskrivelse af revisor:statsautoriseret revisor
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the “Auditor's responsibilities for the audit of the financial statements” section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of Myonex ApS for the financial year 1 January - 31 December 2022, which comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared under the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2022 and of the results of the company's operations for the financial year 1 January - 31 December 2022 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on management's review Management is responsible for management's review. Our opinion on the financial statements døs not cover management's review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of management's review.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
27.04.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
27.04.2024
Ingen nuværende registrering.
Ingen historik.